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Background: Asthma is a common problem in children and, if inadequately controlled, may seriously diminish
their quality of life. Inhaled short-acting beta2 agonists such as salbutamol are usually prescribed as ‘reliever’
medication to help control day-to-day symptoms such as wheeze. As with many medications currently
prescribed for younger children (defined as those aged 2 years 6 months to 6 years 11 months), there has
been no pre-licensing age-specific pharmacological testing; consequently, the doses currently prescribed
(200–1000 μg) may be ineffective or likely to induce unnecessary side effects. We plan to use the interrupter
technique to measure airway resistance in this age group, allowing us for the first time to correlate inhaled
salbutamol dose with changes in clinical response. We will measure urinary salbutamol levels 30 min after
dosing as an estimate of salbutamol doses in the lungs, and also look for genetic polymorphisms linked to
poor responses to inhaled salbutamol.
Methods: This is a phase IV, randomised, controlled, observer-blinded, single-centre trial with four parallel
groups (based on a sparse sampling approach) and a primary endpoint of the immediate bronchodilator
response to salbutamol so that we can determine the most appropriate dose for an individual younger child.
Simple randomisation will be used with a 1:1:1:1 allocation.
Discussion: The proposed research will exploit simple, non-invasive and inexpensive tests that can mostly be
performed in an outpatient setting in order to help develop the evidence for the correct dose of salbutamol
in younger children with recurrent wheeze who have been prescribed salbutamol by their doctor.
Trial registration: EudraCT2014-001978-33, ISRCTN15513131. Registered on 8 April 2015.
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Asthma is a common problem in childhood that, if
inadequately controlled, seriously diminishes quality
of life [1]. Approximately one million UK children have
been diagnosed with asthma, and almost all of them will
have been prescribed a short-acting inhaled beta2 agonist
(usually salbutamol) as a ‘reliever’ medication to help* Correspondence: s.mukhopadhyay@bsms.ac.uk
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(http://creativecommons.org/publicdomain/zecontrol their day-to-day symptoms. Inhaled salbutamol is
thus one of the most commonly prescribed medicines for
children in the UK and many other countries around the
world.
The dose-response relationship of any medicine must
be determined prior to regulatory approval. Such
research is relatively straightforward to perform in
adults, but more difficult for children. As a consequence,
many medicines currently prescribed for children have
not undergone age-appropriate testing and so may not
be effective or may even induce unnecessary side effects.is article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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emphasis on such evaluation in children [2]. The
bronchodilator efficacy of inhaled salbutamol in asthma
has now been established in both older children and
adults [3], as has the minimum effective dose in these
two groups [4]. However, neither efficacy nor minimum
effective dose has been established in younger children
(defined as aged between 2 years 6 months and 6 years
11 months), despite inhaled salbutamol frequently being
prescribed within this age group.
There are a number of consequences of our lack of
knowledge in this area:
1. There is much uncertainty about the optimal dose of
a beta agonist to use for symptom relief (for
example, a variation between individual doses of
2–10 puffs is common practice).
2. There is uncertainty about the optimal dose of a
beta agonist for measuring bronchodilator response
in the diagnosis of asthma.
3. There is uncertainty about whether to use a beta
agonist or alternatives such as ipratropium bromide
or montelukast for symptom relief.
A dose of 2–10 puffs of inhaled salbutamol (appro-
ximately 100 μg per puff ) is currently prescribed in both
primary and secondary care as ‘reliever’ medicine for
young children suffering from recurrent wheeze, a
common feature of asthma in this younger age range.
This dose is almost always administered via a spacer
device, as younger children are unable to coordinate
their breathing in order to inhale the medication directly
from a metered dose inhaler. Following inhalation, the
dose of salbutamol biologically available in the airways
depends on many factors, such as breathing technique
and airway calibre.
The urinary salbutamol level 30 min after the adminis-
tration of an inhaled dose is a reasonable surrogate
measure of the biologically available dose [5]. However,
there are no studies where a specific effort has been
made to collect a urine sample from a young child in
the same manner.
The biologically available dose of salbutamol in the
airway elicits the airway bronchodilator response. It is
difficult to monitor side effects in young children, who are
often unable to report discomfort such as palpitations or
irritability. ‘Hyper-activity’ is a poorly studied problem that
is commonly reported by parents of young children
prescribed relatively large doses of salbutamol. In adults
and older children, the response of the airway to a inhaled
bronchodilator can be measured as changes in airway
resistance or expiratory airflow before and after the
administration of the bronchodilator. Most measures of
airway resistance or airflow require the active co-operationof the patient, but such co-operation is difficult to achieve
in young children. Conventional pulmonary function mea-
surements, such as forced expiratory volume in 1 second or
peak expiratory flow rate, either are impractical or are
relatively unreliable in younger children. However, a tech-
nique relying on the transient interruption of breathing
(known as the interrupter technique) has been recently
developed as a reliable test of airway resistance (Rint) in this
age group. Recent consensus guidelines [6] support the use
of Rint in this age group for the measurement of airway
resistance and for determining response to bronchodilator
medication.
Thus there is now the possibility of correlating inhaled
salbutamol dose with clinical response (measured as
change in Rint) in younger children in the age range
2 years 6 months to 6 years 11 months. It is therefore of
importance to document the airway response to increa-
sing doses of inhaled salbutamol in this age group. To
do this we need to document airway response against
30-min urinary salbutamol, the best available estimate
for the bioavailability of salbutamol in the lungs. With
expert children’s nurse support, we believe that most
young children can be persuaded to pass a sample of
urine at about 30 min following inhalation. However, we
cannot assume that this will happen in all children and
have made this a secondary outcome of the trial.
The proposed work is likely to identify a population of
children who do not show a satisfactory response to
salbutamol. There is evidence from studies in older
children and young adults that one reason for this poor
response may be a genetic change in their beta2 receptor
(Arg/Gly16) [7, 8]. The presence of this polymorphism
can be identified by DNA analysis on a simple saliva
sample, without the need for specialist pulmonary function
equipment. As these samples can easily be obtained in
primary care, we propose to investigate whether this poly-
morphism is an effective marker for poor salbutamol
efficacy in these younger children.
Overall, the proposed research will exploit simple,
non-invasive and inexpensive tests that can mostly be
performed in an outpatient setting in order to help
develop the evidence for the correct dose of salbutamol
in younger children with recurrent wheeze who have
been prescribed salbutamol by their doctor. It is possible
that a small dose of salbutamol, such as 2 puffs (200 μg)
is adequate for most of these children. If this is the case,
larger doses, such as 1000 μg, should not be prescribed
(as is current practice) as they may induce side effects in
these children. Secondly, some younger children who
are currently prescribed larger doses of salbutamol may
in fact be ‘poor responders’ or ‘non-responders’ to salbu-
tamol due to their genetic constitution. Such children
may benefit from alternative ‘reliever’ medicines, such as
ipratropium or montelukast.
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This is a phase IV, randomised, controlled, observer-
blinded, single-centre trial with four parallel groups and
a primary endpoint of the immediate bronchodilator
response to salbutamol so that we can determine the
most appropriate dose for an individual younger child.
Simple randomisation will be used, with a 1:1:1:1 alloca-
tion (see the CONSORT flowchart of Fig. 1).
Methods
Participants, interventions and outcomes
Potential participants will be identified by members of
the direct care team at the Royal Alexandra Children’s
Hospital, Brighton in outpatient or inpatient wards or
the children’s emergency department. The direct clin-
ical care (doctor or nurse) team will then refer the
patient and carer to the research nurse for further
discussion regarding the study. If they are interested
and are happy to meet the research nurse, this will
be arranged. Where appropriate, the patient and carer
are provided with a Patient Information Sheet (PIS).
In some cases this material will be sent by post. AnFig. 1 CONSORT flowchart for the OpSal trialappointment is arranged at the hospital, where any
further queries are addressed. Eligibility criteria are
established by the doctor and consent obtained at this
visit. Informed consent, where offered, will be received
by the research nurse on the day the child attends the
study. The research nurse will have already provided
written information on the study to both carers and
children so they will have had time to consider the
information prior to attending their appointment with
the research nurse. The nurse will also show pictures
of the Rint and saliva collection equipment and dem-
onstrate the equipment. We will ensure that the child
and the carer fully understand the implications of the
consent and that they understand that the consent is
voluntary and will not affect their treatment rights.
Eligibility criteria
Inclusion criteria
The inclusion criteria are as follows:
 Children between the ages of 2 years 6 months and
6 years 11 months
Table 1 Schedule of dose pairs to be tested
Dose studied 100 μg 200 μg 400 μg 600 μg 800 μg
1 √ √
2 √ √
3 √ √
4 √ √
Table 2 Schedule of assessments
Schedule items Enrolment Randomisation Baseline Testing:
Dose 1
Testing:
Dose 2
Time point T0 T45 min
Enrolment
Eligibility
screening
X
Informed
consent/assent
X
Allocation X
Interventions
Dose 1 X
Dose 2 X
Assessments
Clinical history X
Recent
relevant
medications
X
Adverse events X X
Saliva sample
(for DNA work)
X
Rint
assessment
X X X
Urine sampling X X
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three episodes of wheeze over the previous
12 months
Exclusion criteria
The exclusion criteria are as follows:
 Other major airway or lung disease, e.g.
physician-diagnosed chronic lung disease
of prematurity, cystic fibrosis or abnormal
airway anatomy
 Use of long acting beta2 agonists within 1 week
of the study visit
 Treatment with systemic corticosteroids or
leukotriene inhibitors within 2 weeks prior to
the study visit.
 Involvement in a drug study within the last 30 days
Measuring dose response to inhaled salbutamol
using Rint
To span the entire plausible dose-response range in each
individual child would be unethical, requiring an im-
practical long protocol and multiple Rint measurements,
at an age when cooperation is notoriously difficult to
achieve and maintain. We therefore plan to map out the
dose-response curve using a sparse-sampling dosage
schedule in which each individual child will receive just
two successive doses, with Rint measurements at base-
line and after the first and second dose. For the dose-
response assessment using Rint, we used the same
design as the one created by two of the investigators for
a recent study (DORESI study NCT 01470755). There is
an assumption that the measurements made after
administration of the second dose reflect the sum of the
first and second doses, i.e. that the two doses are
additive, with no loss of potency for the first dose during
the interval between the first and second measurements.
The two doses to be administered in each individual
child will be randomly determined from the options
below and will be concealed from the researchers
measuring the response using Rint. Children will be ran-
domised to the four dosage schedules in the ratio 1:1:1:1.
Dosage schedules
The dosage schedules are as follows:
1. 100 μg salbutamol→ +300 μg = 400 μg salbutamol
2. 100 μg salbutamol→ +500 μg = 600 μg salbutamol
3. 200 μg salbutamol→ +600 μg = 800 μg salbutamol
4. 200 μg salbutamol→ +200 μg = 400 μg salbutamol
Thus these four dosage schedules will contribute the
following data points to the dose-response curve cove-
ring the range 100–800 μg (Table 1).A schedule of assessments is given in Table 2.
Rint measurement will be performed at baseline and
15 min after each of the two doses of salbutamol. The
second dose of salbutamol will be given 30 min after the
first dose. If the participant needs to take a broncho-
dilator within 12 h of the study visit, then the research
appointment should be rescheduled. Rint measurements
will be made as specified in the consensus guidelines [6].
Briefly, the child will be seated and breathing quietly
through the apparatus, via a mouthpiece, with nose
occluded by noseclip or fingers and with cheeks sup-
ported. If the child is unable to tolerate or use a mouth-
piece, a facemask will be used for all three measurements.
At each Rint measurement, a minimum of 10 flow inter-
ruptions will be carried out, with inspection of mouth
pressure transients in real time, in order to achieve a
minimum of five technically acceptable interruptions. The
Rint measurement will be calculated as the median value
of all acceptable interruptions.
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haler from ring-fenced hospital stock, stored within
the research office and dispensed by the research nurse.
The inhaler will be labelled according to EU require-
ments. The salbutamol inhalers will not be temperature-
monitored. An accountability log of the doses given, when
and to whom will be kept by the research team. After
administration of the protocol-defined dose, the inhaler
will be returned to the research nurse, the accountability
log updated and the inhaler transferred back to the
clinical trial pharmacy for destruction. Salbutamol in-
halers are licensed products, and for this trial they are
being used in line with established practice, supported by
guidelines, and the dosage schedule does not exceed what
would be stated in the participant’s GP prescription.
Collection of saliva for DNA analysis
Saliva samples will be collected in accordance with the
instructions provided by the manufacturers of the
sampling kits. Trial participants will be asked to spit
directly into a container; for children unable or unwilling
to spit we will collect saliva samples using swabs.
We will use the non-invasive Oragene® DNA collection
kits (http://www.dnagenotek.com) for the collection of
saliva for DNA extraction. The kit provides a median
DNA yield of about 110 μg. The DNA from saliva is
stable in this kit for up to five years at room temperature
due to proprietary reagents that inactivate bacteria and
nucleases in saliva and minimize chemical hydrolysis of
DNA. The DNA will be stored in the Clinical Investiga-
tion and Research Unit, Brighton and Sussex University
Hospitals Trust (BSUHT). It will be shipped as a single
batch to the Medical Research Institute, University of
Dundee at the end of the study for storage in their DNA
bank prior to DNA extraction and Arg/Gly analysis at
codon 16 of the beta2 adrenoreceptor gene.
Collection of urine 30 min after each dose of inhaled
salbutamol
We will endeavour to collect a urine sample from
each trial participant 30 min after each dose of inhaled
salbutamol, as an additional check on the exact dose
delivered to the lungs and therefore absorbed into the
circulation. Given the age of these children, it may be
necessary to accept some variation in the timing of the
sample. The research team includes an experienced
paediatric nurse with expertise in gaining cooperation
from very young children. The urine samples will be
stored frozen at −80 °C in the Clinical Investigation
and Research Unit (BSUHT) and at the end of the
study shipped as a single batch to the School of Phar-
macy and Biomedical Sciences (University of Brighton)
for salbutamol analysis using liquid chromatography
and mass spectrometry (LC/MS).Sample size
Justification for research question 1: defining the optimal
dose of salbutamol
Can we define the dose of inhaled salbutamol that is
appropriate for children aged 2 years 6 months old to
6 years 11 months old with recurrent wheeze?
We plan to compare the difference in change from
baseline between different salbutamol doses. From the
data by Beydon et al. [9], we would define the minimum
clinically important difference (MCID) for paired t tests
as mean −0.23, standard deviation (SD) 0.19, and set the
threshold of significance at 0.01 to account for multiple
t tests. In order to detect a worthwhile difference of this
size between dosages with 90 % power, a minimum of 24
patients will be needed in each dosage group, giving a
sample size of 96 patients.
Justification for research question 2: Arg versus Gly beta
agonist response
Can we predict the salbutamol dose that is appropriate
for an individual child using simple, non-invasive and
inexpensive tests that can be performed in the outpatient
setting?
The hypothesis to be tested is that children with
wheeze who are either homozygous or heterozygous for
arginine at position 16 of the beta2 receptor (i.e. Arg/
Arg or Arg/Gly status) show a diminished peak response
to inhaled salbutamol in comparison to children with
wheeze carrying the Gly/Gly status.
The sample size calculations are based on data pub-
lished by Beydon et al. [9]. Mean baseline Rint in
asthmatic children was 0.92, SD 0.22 kPa/L/s; levels
dropped to 0.74, SD 0.18 kPa/L/s after bronchodilator
administration. In children who did not have asthma,
the baseline Rint dropped by a smaller proportion,
decreasing 0.10 unit to 0.82 kPa/L/s. All the children in
this study will have wheeze. Hence, we feel they will have
a higher baseline airway resistance comparable to children
with asthma, and higher than controls without asthma, as
reported in [9]. However, we estimate that children
carrying one or both copies of Arg will show a diminished
response that is comparable to that of children who do
not have asthma. Thus our sample size calculations are
based on the prediction that the peak bronchodilator
response in the children who have Arg/Arg or Arg/Gly
status will show a mean fall in Rint of 0.10 unit to 0.82
kPa/L/s, whereas the wheezy children who have Gly/Gly
status will show a response that is at least as substantial as
that observed by Beydon et al. [9] in children with asthma
(i.e. a mean fall of 0.18 kPa/L/s).
The ratio of children carrying Arg/Arg and Arg/Gly
status to those with Gly/Gly is 60 %:40 %. A sample size
of 133 (80 Arg and 53 Gly/Gly) would allow us to detect
a difference of 0.08 unit between the groups (delta =
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significance, assuming a correlation between baseline
and post-bronchodilator measurements of 0.6. To allow
randomisation of equal numbers to the four groups, the
sample size should be increased to 136. In order to allow
a sample size sufficiently large to answer both research
questions, and to allow for up to 12 % of children being
unable to perform the measurement (based on experi-
ence in our unit in this age range), we will recruit a sam-
ple size of 156 children. We intend to recruit these
children over 36 months.
Study of the relationship between urinary salbutamol
levels and Rint measurements
The concentration of salbutamol in the urine at
30 min following a dose of salbutamol represents the
gold standard of lung bioavailability. This has been
established in adults. We will try to collect as many
urine samples as possible, and we will aim to study
the dose that is available to the lungs, measured as
the 30 min urine salbutamol, against bronchodilator
response. Data analysis will be performed as discussed
above for inhaled lung dose versus bronchodilator
response. As the production of urine on request is
rather uncertain in children of this age, this is intended
as a distinct secondary analysis. The main project, inclu-
ding the principal outcomes, will not be affected in any
manner if the collection of these samples is incomplete.
Assignment of interventions
Participants will be randomised to the various pairs
of salbutamol doses by a member of the research
team using a web-based system (http://www.sealeden
velope.com/). Those delegated the role of randomising
participants will be assigned a sealed.envelope.com ran-
domisation user name and password by the trial manager.
To randomise a participant, the randomiser will follow the
OpSal Randomisation Guide. The randomisation system
will be accessed at the following website: https://www.sea
ledenvelope.com/bsuh/users.
At the point of consent, a participant identifier will be
assigned to the patient using the Participant Number
Assignment Log. To randomise a participant, the parti-
cipant identifier and date of birth must be entered, and
then the inclusion and exclusion criteria must be
confirmed. The participant is then randomised to a dos-
age schedule. An email notification is then sent to the
randomiser and the coordinating centre.
An allocation sequence has been generated with four
possible dosage schedules on a 1:1:1:1 basis. There is no
stratification. The randomisation code list was generated
by the trial statistician, and it was uploaded onto the web-
based system by the trial manager. The direct research
team members do not have access to the randomisationcode list; therefore, concealment of allocation sequence is
maintained until the moment of assignment.
The researcher performing the Rint measurement on
the participant will be blinded to the dosing schedule
until after the assessment has been performed. Two
members of the research team will be required for the
study visit. Researcher 1 will perform the Rint measure-
ments and will be blinded to the dosage schedule. This
researcher must leave the room whilst the salbutamol is
being administered to the participant and any associated
paper work must be concealed from this researcher until
the study assessments have been performed. Researcher
2 will be unblinded to the dosage schedule. Researcher 2
will randomise the participant using the web-based
randomisation service (sealedenvelope.com) on the day
of the visit and will then administer the salbutamol.
Once the final Rint measurement has been performed,
the dosage schedule can be revealed to members of the
research team if necessary.
In the unlikely event that the blinded researcher needs
to know the dosage schedule given to the participant
and unblinded members of the research team are not
available to disclose it, the dosage schedule for each
participant will be documented in the Case Report Form
(CRF) and filed in the site file. The sponsor will also
retain a copy of the randomisation list and will be
notified of the dosage schedule at the point of rando-
misation via sealed.envelope.com.Data collection, management and analysis
Data collection methods
The majority of data collected for the study will be re-
corded directly into the paper CRF. Source data entered
directly into the CRF will include:
(a)Clinical history with a focus on wheeze and related
atopic diseases
(b)Recent medication in relation to wheeze
(c)Study procedures: salbutamol dosing schedule, Rint
measurements, saliva and urine sampling
The following information must be recorded in the
participant’s health records in addition to the CRF:
(a)Eligibility
(b)Informed consent
(c)Trial number
(d)Adverse events and any other clinically significant
information
(e)Withdrawal from the trial where appropriate
A copy of the original CRF should be kept in the
participant’s health records. The CRF will be faxed or
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Brighton, as per the study-specific CRF completion guide-
lines held in the site file. The original CRF will be stored
in the site file.
Blank and completed copies of the paper CRF will be
stored securely in the site file. Any deviations from the
protocol will be noted on the CRF and documented in
the Protocol Deviation Log stored in the site file.
The information collected during the study, including
the genetic information, will be stored on a database.
The information will be used solely for the purpose of
research into childhood diseases related to inflammation.
This may include sharing anonymised data from the
study with researchers in France and Italy. Explicit
consent from the parent will be obtained for this.
Safety reporting (ICH Guideline E2A 1994)
An adverse event (AE) is defined as any unfavourable
and unintended sign, symptom or disease temporally
associated with the use of an investigational medicinal
product or other protocol mandated intervention.
An adverse reaction (AR) is any untoward and unin-
tended response to an investigational medicinal product
related to any dose administered. All AEs judged by
either the reporting investigator or the sponsor as having
reasonable causal relationship to a medicinal product
qualify as adverse reactions. The expression ‘reasonable
causal relationship’ means to convey in general that there
is evidence or argument to suggest a causal relationship
(possible, probable or definite).
A serious adverse event (SAE) is any AE regardless of
causality that:
 Results in death (during treatment with, and for
30 days after stopping, study drug).
 Is life-threatening, meaning that the patient was at
immediate risk of death from the reaction as it
occurred; i.e. it does not include a reaction which
hypothetically might have caused death had it
occurred in a more severe form.
 Requires hospitalisation or prolongs existing
hospitalisation. Admissions and/or surgical
operations scheduled to occur during the study
period but planned prior to study entry or elective
operations are not considered AEs if the illness or
disease existed before the patient was enrolled in the
trial, provided that it did not deteriorate in an
unexpected manner during the trial (e.g. surgery
performed earlier than planned).
 Results in persistent or significant disability or
incapacity.
 Is a congenital anomaly/birth defect.
 Requires medical intervention to prevent permanent
damage, or another medically important event,defined as an event that may not result in death, be
life-threatening or require hospitalisation but may
be considered an SAE when, based upon appropriate
medical judgment, it may jeopardize the patient
or subject and may require medical or surgical
intervention to prevent one of the outcomes listed
in the definitions for SAEs.
A serious adverse reaction (SAR) is defined as an SAE
that has a definite, probable or possible causal relation-
ship to the study drug (salbutamol). An adverse reaction
is ‘unexpected’ if its nature and severity are not
consistent with the information about the medicinal
product set out in the Summary of Product Characte-
ristics (SmPC). A suspected unexpected serious adverse
reaction (SUSAR) is a drug-related SAR that has not
previously been reported as a drug-related SAR (i.e. is not
listed in the SmPC). Table 3 is taken from the salbutamol
SmPC and lists the adverse events expected when taking
salbutamol. This table should be referred to when deter-
mining the expectedness of an event. Frequencies are
defined as: very common (≥1/10), common (≥1/100 and
<1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000
and <1/1000), very rare (<1/10,000) and not known
(cannot be estimated from available data).
All AEs will be documented in the hospital notes.
ARs will be recorded in the hospital notes and in the
CRF which will be filed in the participant’s hospital
records. SAEs and SARs will be recorded in the hos-
pital notes and the CRF and will be reported to the
sponsor in an expedited fashion as per the relevant
sponsor Standard Operating Procedure (SOP) for Safety
Reporting. Whether expected or not, Table 4 illustrates
how the events should be reported during the study. For
each event the investigator or other medically qualified
doctor on the delegation log will make a documented
assessment of causality, seriousness and expectedness. If
the research team becomes aware of any SARs once
participation has stopped, these will be reported to the
sponsor in an expedited fashion as per the relevant spon-
sor SOP for Safety Reporting.Monitoring
Data monitoring
A formal data monitoring committee will not be con-
vened for this research study. There will be quarterly
reviews of any adverse reactions and serious adverse
events/reactions reported and appropriate action
taken.Monitoring
The monitoring plan for the study will document the
intensity of monitoring required.
Table 3 Adverse events expected when taking salbutamol, taken from the SmPC
Adverse event Common Uncommon Rare Very rare
Immune system disorders Hypersensitivity reactions
(angio-oedema, urticaria,
hypotension and collapse)
Metabolism and nutrition
disorders
Hypokalaemia
Nervous system disorders Headache Hyperactivity, restlessness,
dizziness
Cardiac disorders Palpitations Myocardial ischaemia, cardiac
arrhythmias including atrial
fibrilation, supraventricular
tachycardia and extrasystoles
Vascular disorders Peripheral vasodilatation,
and as a result small
increase in heart rate
Respiratory, thoracic and
mediastinal disorders
Bronchospasm, cough, irritation
of mouth and throat which may
be prevented by rinsing the mouth
after inhalation
Musculoskeletal and
connective tissue and
bone disorders
Tremor Muscle cramps
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The trial may be audited by the sponsor (BSUHT) in
accordance with their annual audit plan.Statistical analysis plan
Rint measurements will be summarised, by dosage arm
and by polymorphism, using means, standard deviations,
medians and interquartile ranges. To answer research
question 1, post-bronchodilator Rint will be regressed
on baseline Rint to increase the precision of the treat-
ment effect estimate, and dosage regimens with 100 +
300 mg of salbutamol taken as the reference group.
Adjusted differences in mean Rint will be reported
together with 99 % confidence intervals and p values,
with p < 0.01 chosen to be significant in light of the
multiple testing. To answer research question 2, exten-
ding the above model, a binary variable indicating homo-
zygosity or heterozygosity for arginine and the interactionTable 4 Procedure for reporting adverse events during the trial
Type of eventa Hospital notes CRF Expedited reporting
(immediately and within 24 h)
Adverse event Yes No No
Adverse reaction Yes Yes No
Serious adverse
event
Yes Yes Yes
Serious adverse
reaction
Yes Yes Yes
aFor definitions see section on Safety reporting (ICH Guideline E2A 1994)
in main textterms between this variable and the dosage regimen
indicator variables will be included in the model.Ethics and dissemination
Research ethics favourable opinion
A favourable opinion from a national research ethics
committee (REC) has been received from the East of
Scotland Research Ethics Service REC 2 (reference 14/
ES/0072) prior to obtaining NHS permissions and com-
mencing the study.
Protocol amendments
Any proposed amendments to the research study will be
discussed with the sponsor. The sponsor will determine
whether the amendment is substantial or not. If the
amendment is deemed substantial, the sponsor will
determine whether the amendment needs review by the
REC, the Medicines for Healthcare Regulatory Agency
(MHRA) or both. The Principal Investigator is respon-
sible for ensuring that the amendments are implemented
and important modifications are communicated to rele-
vant parties when applicable.
Confidentiality
Each participant will be allocated a participant identifier
number at the time of consent. Thereafter, this unique
identifier will be used to identify the participant. The
code list that details which participant identifier number
links with which participant will be kept in a secure,
swipe-access-only area in a locked room.
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The full trial protocol is being published in the online jour-
nal Trials (www.trialsjournal.com). A research summary
will be provided to participants if they request to be made
aware of this. Trial results will be communicated to health-
care professionals, the public and other relevant groups at
conferences and press releases, through published papers in
scientific journals and via parent groups. The primary trial
publication will follow CONSORT reporting guidelines.
Trial sponsor
The trial sponsor is (reference 150400) Brighton and
Sussex University Hospitals NHS Trust (BSUHT),
Royal Sussex County Hospital, Eastern Road, Brighton
BN2 5BE, UK. The sponsor’s representative is Mr
Scott Harfield, BSUHT Research and Development
Manager, telephone + (44) 01273 696955, email scott.
harfield@bsuh.nhs.uk.
The sponsor (BSUHT) has had no role in the design
of this study. Their role in the study will be limited to
governance issues such as determining whether any
proposed amendments to the current protocol are
substantial or not. Other than this governance role, the
sponsor will not be involved in the execution of the
study, data analyses, interpretation of the data or the
decision to submit results for publication. The funder’s
reviewers have made various suggestions in terms of
study design but will not have any role during its
execution, data analyses, interpretation of the data or
the decision to submit results for publication.
Committees
Trial Steering Committee (TSC)
The TSC consists of Gemma Earl (Chair), Somnath
Mukhopadhyay, Paul Seddon and Emma Wileman. The
TSC will provide overall supervision for the trial,
monitoring its progress and ensuring adherence to the
protocol and the principles of Good Clinical Practice
(GCP). The TSC will focus on recruitment, adherence to
the protocol, participant safety and any considerations
based on new information emerging during the trial.
Data monitoring committee (DMC)
As this trial involves a licensed medicine with an exten-
sively researched safety profile that will be previously
have been used by all potential participants, the sponsor
has agreed that a DMC will not be convened.
Trial status
The trial is now open, with 37 children recruited as of
June 2016.
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